BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18792078)

  • 1. A Bayesian model averaging approach for cost-effectiveness analyses.
    Conigliani C; Tancredi A
    Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian model averaging approach with non-informative priors for cost-effectiveness analyses.
    Conigliani C
    Stat Med; 2010 Jul; 29(16):1696-709. PubMed ID: 20572119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
    Heitjan DF; Li H
    Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW; Montmartin J
    Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-parametric modelling for costs of health care technologies.
    Conigliani C; Tancredi A
    Stat Med; 2005 Oct; 24(20):3171-84. PubMed ID: 15568210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
    Spiegelhalter DJ; Best NG
    Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-sample Bayesian posterior distributions for probabilistic sensitivity analysis.
    Hazen GB; Huang M
    Med Decis Making; 2006; 26(5):512-34. PubMed ID: 16997928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parametric modelling of cost data in medical studies.
    Nixon RM; Thompson SG
    Stat Med; 2004 Apr; 23(8):1311-31. PubMed ID: 15083485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
    Nixon RM; Wonderling D; Grieve RD
    Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane.
    Negrín MA; Vázquez-Polo FJ
    Health Econ; 2006 Apr; 15(4):363-72. PubMed ID: 16259048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data.
    Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG
    Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian regression models for cost-effectiveness analysis.
    Polo FJ; Negrín M; Badía X; Roset M
    Eur J Health Econ; 2005 Mar; 6(1):45-52. PubMed ID: 15517461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of branch length uncertainty on Bayesian posterior probabilities for phylogenetic hypotheses.
    Kolaczkowski B; Thornton JW
    Mol Biol Evol; 2007 Sep; 24(9):2108-18. PubMed ID: 17636043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
    Elbasha EH
    Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of net-costs for prevention of occupational low back pain: three case studies from the US.
    Lahiri S; Gold J; Levenstein C
    Am J Ind Med; 2005 Dec; 48(6):530-41. PubMed ID: 16299707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.